Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 Slide Shows
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
CES 2010 Coverage 

Follow Us
RTTNews on Twitter RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

Font Down Font Up

 
Amylin And Eli Lilly's Diabetes Injection Gets FDA Nod For Stand-alone Use - Update
10/30/2009 9:02 PM  ET
RELATED NEWS
Amylin Q4 Loss Narrows - Update
Amylin Pharmaceuticals Q4 Loss Narrows - Quick Facts
Amylin Pharma Q4 09 Earnings Conference Call At 5:00 PM, ET
Amylin Pharmaceuticals Closed Tuesday At New High For Year
Amylin Pharmaceuticals Closed At New High For Year Wednesday

Trade AMLN now with
TOP MARKET NEWS
Stocks Hovering Near Highs In Mid-Afternoon Trading - U.S. Commentary
Obama Meets With House And Senate Leaders In Effort To Boost Bipartisanship
Opel/Vauxhall Unveils €11 Bln Investment Plan; To Cut 8,300 Jobs
Stocks Building On Strong Gains In Early Afternoon Trading - U.S. Commentary
House GOP Leaders Demand White House Scrap Health Reform Legislation Prior To Summit
(RTTNews) -  Friday after the bell, Amylin Pharmaceuticals, Inc. (AMLN: News ), along with with Eli Lilly & Co. (LLY: News ) announced the U.S. Food and Drug Administration or FDA's approval for expanded indication of their injectable diabetes drug Byetta, to be given as a stand-alone medication to improve glycemic control in patients with type-2 diabetes, when used along with diet and exercise.

Byetta has already been approved by the FDA as a glycemic-control medication in type-2 diabetics using other common diabetes medications and who had not achieved adequate glycemic control.

The approval was based on reports from a clinical study, which proved that the treatment with 5mcg and 10mcg of Byetta reduced average blood sugar levels, measured as A1C levels, by 0.7% to 0.9%, over a three-month period. The study involved patients with type 2 diabetes who were unable to achieve glycemic control through diet and exercise alone. The patients also lost 6.0 pounds and 6.4 pounds, on using the injection, according to the company.

In reporting adverse events from the trial, the company noted that nausea was reported with the greatest incidence, 3% in 5mcg cohort and 13% in 10mcg cohort. Hypoglycemia was reported in 5% of patients taking 5mcg and 4%t of patients taking 10mcg, with no severe hypoglycemic events.

BYETTA is the first and only FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. The drug improves blood sugar levels after food intake through multiple effects on the stomach, liver, pancreas and brain. Used by more than one million patients since introduction in 2005, Byetta has been prescribed in 10 million cases until today, according to the company.
Type-2 diabetes is a disorder characterized by high blood glucose, when the body develops a resistance or a relative deficiency to blood glucose-reducing-hormone, insulin. The condition worsenes the body condition by affecting eyes, feet, kidneys and various other complications in the longer-run. There are an estimated 23.6 million people in the U.S. with diabetes with 17.9 million being diagnosed, 90% of whom are type 2.

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60%of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen. In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese, added the company.

To receive FREE breaking news email alerts for Amylin Pharmaceuticals Inc and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print           Follow Us RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

     
 

More Breaking News-US

83  Apple Unveils Aperture 3 Photo Editing And Management Software - Update
82  IBM Signs 5-yr Remote Managed Services Agreement With Sandhar Technologies - Update
81  Semiconductor Manufacturing Q4 Loss Widens; Appoints New CBO, COO And CFO - Update
80  Partner Communications Q4 Profit Up - Update
79  ATA Automation Q3 Profit Declines - Update
78  Triple-S Management Q4 Profit Up, Tops View - Update
77  Microsoft, Interpublic Group In Ad-server Solution Deal - Update
76  Stepan Q4 Profit Surges - Update
75  Centene Q4 Profit Up - Update
74  Delta Responds To Japan Airlines Decision To Stay With American - Update
73  American Commercial Lines Q4 Profit Down - Update
72  OJSC VimpelCom Board Recommends Exchange Offer By VimpelCom Ltd - Update
71  American Airlines Says It Is Pleased With Japan Airlines' Continuing Membership In Oneworld Alliance - Update
70  Nabors Industries Expects Q4 Above Street Estimates - Update
69  RiskMetrics Swings To Q4 Profit - Update
  

 

Copyright © 2010 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service| How To Use RTTNews.com| Advertise| Privacy| Buy Content | RSS